Healthcare Industry News: Indevus Pharmaceuticals
News Release - May 10, 2012
Incline Therapeutics Announces Appointment of John Tucker as Chief Commercial OfficerREDWOOD CITY, Calif., May 10, 2012 -- (Healthcare Sales & Marketing Network) -- Incline Therapeutics, Inc., a hospital-focused specialty pharmaceutical company, announced today the appointment of John Tucker as Senior Vice President and Chief Commercial Officer. Mr. Tucker has 20 years of experience building and leading pharmaceutical commercial organizations with a significant focus in the hospital market. He will serve as a member of Incline's senior leadership team and have broad responsibility for sales, marketing, and other commercial operations.
Mr. Tucker joins Incline from AMAG Pharmaceuticals where he was Vice President, Commercial Operations responsible for all sales and marketing activities with a primary focus on the hospital sector. Previously, he was President, U.S. Operations at Basilea Pharmaceuticals where he developed the commercial strategy and organization for the planned launch of a hospital-focused product. Prior to Basilea, Mr. Tucker was Executive Vice President, Sales and Marketing at Indevus Pharmaceuticals. Earlier in his career, he held a variety of both hospital and retail-based sales and marketing positions with increasing levels of responsibility at Ortho-McNeil Pharmaceuticals, ALZA Corporation, VIVUS, and UCB Pharma. Mr. Tucker holds a B.A. from Plymouth State College and an M.B.A. from New Hampshire College.
"We are very pleased to welcome John to Incline as we prepare for the launch of our lead product candidate, IONSYS," said Alan Levy, Ph.D., Chief Executive Officer of Incline. "His extensive hospital sales and marketing experience and his demonstrated track record of outstanding commercial leadership will be pivotal to the future success of the company. We look forward to John's contributions."
About Incline Therapeutics, Inc.
Incline Therapeutics is a hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system), a compact, disposable, needleless patient-controlled system for the short-term management of acute postoperative pain in adult patients requiring opioid analgesia during hospitalization. IONSYS has completed Phase III development and was previously approved in the United States and Europe. Prior to marketing IONSYS, Incline must seek approval of a supplemental New Drug Application (sNDA) in the United States and a Marketing Authorization Application (MAA) in Europe. Incline is led by a management team with significant pharmaceutical and medical device experience and financed by leading life science venture capital firms, including Frazier Healthcare Ventures, 5AM Ventures, Technology Partners, Adams Street Partners, and Saints Capital. The company is based in Redwood City, California.
Incline™ and IONSYS™ are trademarks of Incline Therapeutics, Inc.
Source: Incline Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.